Numerous　studies　have　confirmed　that　vascular　endothelial　growth　factor　(VEGF)　improves　the　function　of　neural　cells　following　spinal　cord　injury　(SCI).　However,　some　studies　have　also　verified　that　VEGF　cannot　significantly　induce　the　increase　in　vascular　density　at　or　surrounding　the　lesion,　and　that　VEGF　therapy　exacerbated　secondary　damage　following　SCI.　Based　on　the　dual　effects　of　VEGF　on　SCI,　we　constructed　the　recombinant　adeno-associated　viruses　(rAAV)-hVEGF(165)-IRES-human　recombinant　green　fluorescent　protein　(hrGFP)　(AAV-VEGF)　and　rAAV-IRES-hrGFP　(AAV-GFP).　Our　results　suggested　that　rAAV　expressed　hVEGF(165),　and　a　low　dose　of　VEGF　relieved　increased　vascular　permeability,　improved　microcirculation　in　the　local　spinal　cord,　lessened　spinal　cord　edema,　and　decreased　neuronal　apoptosis.　These　results　verified　that　the　releasing　effects　of　the　rAAV　virus　vector　had　protective　effects　on　the　spinal　cord.